nature portfolio

| Corresponding author(s): | Maarten J. H. I. Beekman |
|----------------------------|--------------------------|
| Last updated by author(s): | |

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

| _ | | | | |
|---|-----|----|----|-----|
| 5 | ta: | t١ | c† | ics |

| For all statistical an | alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. | | |
|--|--|--|--|
| n/a Confirmed | | | |
| The exact | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement | | |
| A stateme | nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly | | |
| The statist Only comm | The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. | | |
| A descript | ion of all covariates tested | | |
| A descript | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons | | |
| A full desc | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) | | |
| For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable. | | | |
| For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings | | | |
| For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes | | | |
| \square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated | | | |
| Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. | | | |
| Software and | d code | | |
| Policy information a | about <u>availability of computer code</u> | | |
| Data collection | Data collection Described in the methods section. | | |
| Data analysis | Data analysis Described in the methods section. | | |
| For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information. | | | |
| Data | | | |
| | | | |

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data sharing statement included in the manuscript.

| Research inv | olving hui | man participants, their data, or biological material |
|---|------------|--|
| Policy information a and sexual orientation | | vith |

Timing

Data exclusions

Non-participation

Randomization

| olutionary & environmental sciences study design |
|--|
| hese points even when the disclosure is negative. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| work? Yes No |
| |
| |
| |
| |
| thors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, and to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Methods |
| t i |

Antibodies

| Antibodies used | Not applicable |
|-----------------|----------------|
| Validation | Not applicable |

| Eukaryotic cell lines | |
|--|---|
| Policy information about <u>cell l</u> | ines and Sex and Gender in Research |
| Cell line source(s) | |
| Authentication | |
| Mycoplasma contamination | |
| Commonly misidentified line (See ICLAC register) | 25 |
| Palaeontology and | Archaeology |
| Specimen provenance | |
| Specimen deposition | |
| Dating methods | |
| Tick this box to confirm t | that the raw and calibrated dates are available in the paper or in Supplementary Information. |
| Ethics oversight | |
| Note that full information on the | approval of the study protocol must also be provided in the manuscript. |
| | research organisms ies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in |
| <u>Research</u> | |
| Laboratory animals | |
| Wild animals | |
| Reporting on sex | |
| Field-collected samples | |
| Ethics oversight | |
| Note that full information on the | approval of the study protocol must also be provided in the manuscript. |
| Clinical data | |
| Policy information about clinic | |
| Clinical trial registration | th the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions. |
| Study protocol | |
| Data collection | |
| | |
| Outcomes | |

Dual use research of concern

Policy information about <u>dual use research of concern</u>

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

| No Yes Public health National security Crops and/or livest Ecosystems Any other significan | |
|---|--|
| Experiments of concer | n |
| Does the work involve any | y of these experiments of concern: |
| Confer resistance to Enhance the viruler Increase transmissi Alter the host range Enable evasion of conference in Enable the weapon | |
| Plants | |
| Seed stocks | |
| Novel plant genotypes | |
| Authentication | |
| ChIP-seq | |
| Data deposition | and final processed data have been deposited in a public database such as <u>GEO</u> . |
| | deposited or provided access to graph files (e.g. BED files) for the called peaks. |
| Data access links May remain private before public | ation. |
| Files in database submissi | on |
| Genome browser session (e.g. <u>UCSC</u>) | |
| Methodology | |
| Replicates | |
| Sequencing depth | |
| Antibodies | |
| Peak calling parameters | |
| Data quality | |

| Software |
|---|
| Flow Cytometry |
| Plots Confirm that: The axis labels state the marker and fluorochrome used (e.g. CD4-FITC). The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers). All plots are contour plots with outliers or pseudocolor plots. A numerical value for number of cells or percentage (with statistics) is provided. |
| Methodology |
| Sample preparation |
| Instrument |
| Software |
| Cell population abundance |
| Gating strategy |
| Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information. |
| Magnetic resonance imaging |
| Experimental design |
| Design type |
| Design specifications |
| Behavioral performance measures |
| |
| Imaging type(s) |
| Field strength |
| Sequence & imaging parameters |
| Area of acquisition |
| Diffusion MRI Used Not used |
| Preprocessing |
| Preprocessing software |
| Normalization |
| Normalization template |
| Noise and artifact removal |
| Volume censoring |
| Statistical modeling & inference |
| Model type and settings |
| Effect(s) tested |
| |

| nature portfolio |
|------------------|
| reporting su |
| summan |

| \rightarrow | |
|---------------|---|
| | |
| ≂ | |
| | |
| _ | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| ۶ | |
| | |
| Ķ | |
| | |
| | |
| | ١ |
| | |
| | |
| | |
| | |
| | |

| Specify type of analysis: |
|---|
| Statistic type for inference |
| (See Eklund et al. 2016) |
| Correction |
| Models & analysis |
| n/a Involved in the study |
| Functional and/or effective connectivity |
| Graph analysis |
| Multivariate modeling or predictive analysis |
| Functional and/or effective connectivity |
| Graph analysis |
| Multivariate modeling and predictive analysis |